


SiroTrust[®]

Advanced Sirolimus-Coated Balloon
Catheter Technology



ORDERING INFORMATION CORONARY APPLICATION (0.014" PTCA GUIDE WIRE) Rx

	10	15	20	25	30	35	40
1.50	ST15010	ST15015	ST15020	ST15025	ST15030	ST15035	ST15040
2.00	ST20010	ST20015	ST20020	ST20025	ST20030	ST20035	ST20040
2.25	ST22510	ST22515	ST22520	ST22525	ST22530	ST22535	ST22540
2.50	ST25010	ST25015	ST25020	ST25025	ST25030	ST25035	ST25040
2.75	ST27510	ST27515	ST27520	ST27525	ST27530	ST27535	ST27540
3.00	ST30010	ST30015	ST30020	ST30025	ST30030	ST30035	ST30040
3.50	ST35010	ST35015	ST35020	ST35025	ST35030	ST35035	ST35040
4.00	ST40010	ST40015	ST40020	ST40025	ST40030	ST40035	ST40040

Additional sizes available upon request

For more information or to place an order:



Factory: Plot No. 5305, 4th Phase, G.I.D.C.,
Vapi - 396195 Gujarat, India
Customer Service :
Email : dcbs@veritasbio.com
Website : www.veritasbio.com



SIROTRUST[®] is a registered trademark. All rights reserved.*
*This brochure is intended for healthcare professionals only

SiroTrust[®]

Advanced Sirolimus-Coated Balloon
Catheter Technology




| www.veritasbio.com

SiroTrust[®]

Advanced Sirolimus-Coated Balloon Catheter Technology

INNOVATIVE TREATMENT FOR VASCULAR DISEASE



SIROTRUST[®] represents the latest advancement in drug-coated balloon (DCB) technology, designed to deliver optimal therapeutic outcomes for patients with Coronary Arterial Disease (CAD) and Peripheral Arterial Disease (PAD). By combining precise drug delivery with minimally invasive balloon angioplasty, SIROTRUST[®] helps restore blood flow while inhibiting restenosis.

CLINICAL ADVANTAGES

- **Sustained Drug Delivery:** Optimized sirolimus coating ensures controlled release for maximum efficacy
- **LMSC (Linear Motion Spray Coating) Technology:** to ensure equal distribution of the drug throughout the balloon
- **Reduced Restenosis Rates:** Clinically proven to significantly decrease vessel re-narrowing compared to standard balloon procedures.
- **Durable Results:** Long-term patency with reduced need for reintervention
- **Vessel-Friendly Design:** Minimizes vascular trauma during deployment and inflation
- **No Permanent Implant:** Leaves nothing behind after treatment, preserving future treatment options

SIROTRUST[®] FEATURES

Optimized Drug Coating

- Precise 1.27 $\mu\text{g}/\text{mm}^2$ sirolimus dose density
- Homogeneous coating distribution
- Enhanced drug transfer to vessel wall
- Proprietary excipient matrix for controlled release

Advanced Balloon Technology

- Low-profile crossing capability
- High-pressure rating for optimal lesion dilation
- Controlled inflation/deflation characteristics
- Superior trackability and pushability

Comprehensive Size Range

- Diameters: 1.5 mm to 4.0 mm
- Lengths: 10 mm to 40 mm
- Compatible with 0.014" and 0.018" guidewires

SIROTRUST[®] INDICATIONS

- Percutaneous transluminal angioplasty (PTA) of de novo or restenotic lesions in:
 - Coronary artery
 - Superficial femoral artery
 - Popliteal artery
 - Infrapopliteal arteries
- Treatment of in-stent restenosis
- Revascularization of below-the-knee vessels

SAFETY INFORMATION

Sirolimus-coated balloons should be used according to their approved indications and with consideration of the appropriate benefit-risk profile for each patient. Healthcare providers should discuss the benefits and risks of all available PAD treatments with their patients.

Important Safety Information:

- Not for use in patients with known hypersensitivity to sirolimus
- Contraindicated in pregnant or breastfeeding women
- Careful consideration required for patients unable to receive recommended antiplatelet therapy
- Review full prescribing information before use